Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Dexcom (DXCM – Research Report) yesterday and set a price target of ...

DexCom's newest G7 CGM competes closely with Abbott's FreeStyle Libre 3, both products have very similar features and design innovations. DexCom's forward multiples suggest the company is trading ...

DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today the launch of the third season of Dexcom U, the company's ...

today announced the Dexcom G6 Continuous Glucose Monitoring (CGM) System is being worn by astronauts in space as part of the Polaris Dawn mission, which launched this morning and aims to better ...

New continuous glucose monitoring sensors (small sensors that ... and two major manufacturers of glucose monitoring sensors, Dexcom and Abbott, just launched products that can now be bought ...

has cleared the Eversense 365 continuous glucose monitoring (CGM) system for patients aged 18 years and older with type 1 or type 2 diabetes. Eversense ® 365 is a fully-implantable CGM with a 365 ...

Senseonics and Ascensia Diabetes Care have announced that the U.S. Food and Drug Administration has cleared the next-generation Eversense 365 CGM, the first one-year CGM system ...

Continuous glucose monitoring, compared with fingerstick tests, was feasible and accurate in an inpatient setting among patients and nurses.

The system is designed for adults with Type 1 and Type 2 diabetes and is comparable to its predecessor, the 180-day Eversense CGM, with an integrated continuous glucose monitoring (iCGM ...

Senseonics Holdings (NYSE: NYSE:SENS) has maintained a Neutral rating from BTIG following the announcement that the company received FDA clearance for its 365-day Eversense continuous glucose ...